supramolecular active zinc
ApprovedSmall molecule
supramolecular active zinc is one of 11 small molecule programs targeting Folliculitis. It is currently in Approved.
1
Indications
2
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Folliculitis
#DrugCompanyPhaseTrials
1Lotrimin
BayerApproved
Ornidyl
UUSWM, LLC (dba US WorldMeds)
Approved
Qvar
SSchering-Plough
Approved
Garamycin
SSchering-Plough
Approved
Olumiant
Eli LillyPhase 2
Alphagan
AbbViePhase 2
Stelara
Johnson & JohnsonPhase 2
Humira
CCelltrion
Phase 2
supramolecular active zinc
SSecond Affiliated Hospital of Xi'an Jiaotong University
Approved
Diprosone
LEO PharmaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Photoaging1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for supramolecular active zinc. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details